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Abstract
Background: In HIV and hepatitis C virus (HCV) coinfected patients, the role of antiretroviral therapy (ART) on
hepatic steatosis (HS) remains controversial.
Methods: HIV/HCV coinfected patients receiving ART and previously untreated for HCV who underwent a liver
biopsy were included. Cumulative duration of exposure to each antiretroviral was recorded up to liver biopsy date.
Logistic regression analyses evaluated factors associated with steatosis and its severity.
Results: 184 patients were included: median age 41 years, 84% male, 89% Caucasian, 61% with a past history of
intravenous drug use. HCV genotypes were 1 (55%), 2 (6%), 3 (26%), and 4 (13%). Median HCV-RNA was 6.18 log10
IU/ml. HIV-RNA was undetectable (<400 copies/ml) in 67% of patients. Median CD4 count was 321/mm3. All
patients had been exposed to nucleoside reverse transcriptase inhibitors (median cumulative exposure 56 months);
126 received protease inhibitors (23 months), and 79 non-nucleoside reverse transcriptase inhibitors (16 months). HS
was observed in 102 patients (55%): 41% grade 1; 5% grade 2, and 9% grade 3. In multivariate analysis, HCV
genotype 3 and HCV viral load were moderately associated with mild steatosis but strongly with grade 2-3 steatosis.
After adjustment for the period of biopsy, no association was detected between HS and exposure to any
antiretroviral class or drug, or duration of ART globally or comparing genotype 3 to others.
Conclusions: Among our ART-treated HIV-HCV cohort predominantly infected with genotype 1, 55% of patients
had HS which was associated with HCV-related factors, but not ART class or duration of exposure.
Keywords: HIV, HCV, steatosis, antiretroviral drugs, genotype 3
Introduction
As a result of shared transmission routes, hepatitis C virus
(HCV) infection is common in patients infected with
human immunodeficiency virus (HIV) [1-3]. In the USA
and Western Europe, at least 30% of HIV-infected patients
are also infected with HCV [1-4]. The immunosuppression
induced by HIV accelerates the natural history of HCV-
related liver disease and the progression of chronic hepa-
titis C to cirrhosis and end-stage hepatic disease [5-10].
The introduction of highly active antiretroviral therapy
has been associated with a dramatic decline in the morbidity
and mortality related to specific HIV complications, whereas
that related to liver disease has increased significantly in
coinfected patients [1,6,11-13]. The relative increase in mor-
bidity and mortality due to liver disease in the HIV popula-
tion is a composite of accelerated liver disease progression
in HCV patients and extended survival of these individuals
due to the benefit of antiretroviral therapy (ART).
Hepatic steatosis (HS), defined by the accumulation of
lipid droplets in hepatocytes, is present in 24-75% of HIV
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and HCV coinfected patients [12,14-23]. Some factors con-
tributing to the development of HS in the general popula-
tion, such as visceral obesity, alcohol consumption,
hypertriglyceridemia, hypertension and diabetes mellitus
remain hugely discrepant during coinfection [24-28]. In
HIV and HCV coinfected patients, HS may occur as a re-
sult of the HIV infection or as a consequence of concomi-
tant HCV infection, as well as metabolic factors such
diabetes, obesity or antiretroviral drugs which could in-
duce metabolic syndrome, lipodystrophy or lactic acidosis
due to mitochondrial damage [12,14,15,18-20,22,29-32].
Nevertheless, the role of ART, particularly stavudine ex-
posure, remains controversial. Moreover, in some studies,
HS appears to be more common and severe in coinfected
than in HCV-monoinfected patients [16,22] and influence
by the viral genotype [16,22]. Borghi et al., showed previ-
ously that HIV related steatosis increase in genotype 3
patients and a putative role of ART in patients infected by
HCV genotype other than 3 [23]. Other factors besides
immunesuppression account for faster progression to
ESLD in coinfected patients (i.e. HIV hepatocyte infection,
drug liver toxicity).
To assess the prevalence and risk factors of HS, par-
ticularly characteristics associated with severity, we
reviewed the epidemiological, clinical and biological data
of HIV-HCV coinfected patients receiving ART, before
HCV therapy and at the time of liver biopsy. Moreover,
we compared the effect of ART according to the
genotype.
Patients and Methods
Patients
For this study, HIV-HCV coinfected patients were retro-
spectively screened in histopathology databases of two
hospitals. All HIV-infected patients with detectable HCV
RNA load (qualitative or quantitative detection), receiving
ART but naive of HCV-specific therapy and who under-
went a liver biopsy between January 1995 and January
2008, were included. When repeated liver biopsies were
performed, only data associated with the first one was
studied.
Patients were excluded if they were positive for hepa-
titis B surface antigen, had a negative plasma HCV RNA
load, or other chronic liver diseases, such as autoimmune
hepatitis, hemochromatosis, Wilson’s disease or alpha-1
antitrypsin deficiency. All patients have been tested for
all of these parameters and the patients included were
negative.
At the day of liver biopsy, the following variables were
assessed: age, gender, ethnicity, alcohol (reported by phys-
ician in the medical report, but no data about the quantity
consumed daily), intravenous drug abuse, duration of docu-
mented HIV and HCV infections, risk factors for viral
transmission, CD4 cell count, HIV and HCV plasma levels,
HCV genotype, fasting glycemia, total cholesterolemia and
triglyceridemia, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), gammaglutamyl transferase (GGT)
and alkaline phosphatase. Measure of insulinemia, not per-
formed in clinical practice, was not available in this retro-
spective study, nor measure of weight, body mass index and
waist circumference which were not recorded in the
medical report. Metabolic parameters were also
recorded for each patient on a fasting state. For the pur-
poses of this study, metabolic syndrome was defined as
triglycerides >1.7 mmol/l and glycemia ≥5.6 mmol/l as
recommended by the International Diabetes Federation
2005 and diabetes as a fasting glycemia> 7 mmol/l and
excluded waist circumference [33].
HCV RNA detection was performed using a signal amp-
lification nucleic acid probe assay (bDNA 3.0, Bayer diag-
nostics, Tarrytown NY) and was expressed in KIU/ml. All
biological data were assessed directly to the data system of
the different laboratories of the 2 hospitals. All of the para-
meters collected were routinely performed in HIV-HCV
patients who underwent a liver biopsy and were assessed
on the day of biopsy or during the week before.
History of antiretroviral therapy was assessed in the
medical report and from our database (Nadis softwareW).
The cumulative duration of exposure to each drug and
class of drugs was recorded for each patient up to the
date of liver biopsy. As patients could have received
more than one ART regimen, and because of the large
diversity of regimens available in France, it would be im-
possible to select specific drug combinations for analysis.
Therefore, we hypothesized that a relationship between a
combination of drugs and severity of HS would be evi-
dent by studying each component of the combination.
Histologic evaluation
Percutaneous or transjugular liver biopsy specimens were
fixed in formalin and embedded in paraffin. Minimal size
was 10 mm and contained at least 6 portal spaces,
excepted if cirrhosis. Sections 4 μm thick were stained
with hematoxylin and eosin, with picrosirius stain for
collagen and Perls’ stain for iron. All liver biopsy speci-
mens were evaluated by two experienced pathologists,
one in each hospital (F.C. or P.B.).
The grade of activity and the stage of fibrosis were evalu-
ated according to the METAVIR scale [34]. Necroinflam-
matory activity was graded A0 (none), A1 (mild), A2
(moderate) or A3 (high). The degree of portal and septal fi-
brosis was assessed as F0 (none), F1 (portal fibrosis with-
out septa), F2 (portal fibrosis with a few septa), F3 (portal
fibrosis with numerous septa) or F4 (cirrhosis). HS was
evaluated and graded as proposed by Brunt et al. [33]:
grade 0, none; grade 1, steatosis involving <33% of hepato-
cytes; grade 2, 33-66% and grade 3, >66%. HS was defined
as mild (grade 1) or severe (grade 2-3).
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Statistical analysis
Median and interquartile ranges (IQRs) described continu-
ous variables. Comparisons between patients found with
and without steatosis were performed using Kruskal-
Wallis or Wilcoxon tests for quantitative variables, and χ2
test or Fisher’s exact test for qualitative variables. Logistic
regression analyses were used to identify determinants of
liver steatosis, and polytomous logistic regression analyses
evaluated factors associated with the presence of mild or
severe steatosis.
Exposure to ART was studied after adjustment for the
period of biopsy (1995-1998, 1999-2001, 2002-2008).
The periods were chosen at the time of the statistical
analysis according to the introduction of drugs such as
abacavir in 1999 and tenofovir in 2002 to show an im-
pact of the use of more “metabolic friendly” drugs. Ex-
posure to ART and cumulative exposure duration (per
1 year increased) were evaluated globally for all patients
and according to genotype: genotype 3 compared to
others.
Variables with p< 0.15 in univariate analyses were
included in the final model. Analyses were processed
with the use of SAS software (SAS Institute, Cary, North
Carolina, USA).
Results
Study population
Between January 1995 and January 2008, 250 HIV-HCV
coinfected patients who underwent a liver biopsy and
fulfilled all inclusion criteria were evaluated. Sixty-six
patients were not analyzed for the following reasons cor-
responding to exclusion criteria: hepatitis B coinfection
(n = 28), loss of medical records (n = 8) or no ART at the
time of biopsy (n = 30). Therefore, 184 patients were
included. Demographic and biological characteristics are
summarized in Table 1.
No correlation was observed between the duration of
HIV infection and CD4 cell count in this cohort of ART-
treated patients. HIV plasma viral load was undetectable
(<400 copies/ml) in 119 out of the 178 (67%) evaluable
patients and median HIV viral load on average was 3.93
log10 copies/ml for the remaining 33% patients. The me-
dian HCV viral load was 6.18 log10 IU/ml (IQR 5.76-
6.60) in the 148 (80%) patients with quantificative HCV
values. The other patients (n = 36) had only a positive
HCV RNA without quantification.
All patients had been exposed to a nucleoside reverse
transcriptase inhibitor (NRTI), including zidovudine
(n=144), lamivudine (n=161), stavudine (n=114), zalcita-
bine (n=22), didanosine (n=105), tenofovir (n=24) and
abacavir (n=24); 126 patients had received protease inhibi-
tors (PI), including ritonavir as boosted-PI (n=59), indina-
vir (n=68), nelfinavir (n=47), saquinavir (n=16), lopinavir
(n=17) and atazanavir (n=8); and 79 patients had received
Table 1 Characteristics of HIV-HCV coinfected patients
treated with antiretroviral therapy at the time of liver
biopsy (parameters collected the day of the liver biopsy
or during the week before)
n=184
Median age at biopsy (IQR), years 41 (36-45)
Male, n (%) 154 (84)
Ethnicity, n (%)
Caucasian 163 (89)
Black 21 (11)
Intravenous drug use, n (%) 127 (61)
Alcohol use, n (%)* 67 (36)
Median duration of HIV diagnosis (IQR, years 11 (7-14)
Median CD4 cell counts/mm3 (IQR) 321 (227-461)
Undetectable HIV RNA+, n (%) 119 (67)
HCV genotype++, n (%)
1 98 (55)
2 10 (6)
3 47 (26)
4 24 (13)
Median HCV RNA (IQR), log10 KIU/ml
+++ 6.18 (5.76-6.60)
Median laboratory variables (IQR), U/l
ALT 83 (47-128)
AST 65 (43-97)
Alkaline phosphatase 89 (71-113)
GGT 80 (42-160)
Median glycemia (IQR), mmol/l 4.8 (4.3-5.3)
Glycemia ≥5.6 mmol/l+, n (%) 33 (19)
Glycemia≥ 7.0 mmol/l+, n (%) 7 (4)
Median total cholesterol (IQR), mmol/l 4.20 (3.54-5.10)
Median triglyceridemia (IQR), mmol/l°° 1.49 (0.99-2.10)
Triglyceridemia ≥1.7 mmol/l+, n (%) 60 (36)
Median duration of antiretroviral therapy (IQR), months 58 (28-94)
Median cumulative exposure to antiretrovirals (IQR),
months
NRTI 56 (28-90)
NNRTI 16 (9-31)
PI 23 (12-40)
Combination of ART at liver biopsy, n (%)
2 NRTI + 1 PI 93 (51)
2 NRTI + 1 NNRTI 36 (20)
1 or 2 NRTI 31 (16)
3 NRTI 17 (9)
Other regimens 7 (4)
+ proportions calculated on available data.
+ Data missing for 6 patients; ++ Data missing for 5 patients; +++ Data missing
for 36 patients; ° Data missing for 11 patients; °° Data missing for 18 patients.
*Alcohol: no quantification was available.
Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; GGT,
gamma-glutamyl transpeptidase; IQR, interquartile range; NNRTI, non-
nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
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non-nucleoside reverse transcriptase inhibitors (NNRTI),
including efavirenz (n=51) and nevirapine (n=44).
Histologic findings
Overall, 102 (55%) out of the 184 patients had HS. Steatosis
was grade 1 in 76 (41%) patients, grade 2 in 10 (5%), and 3
in 16 (9%). Macrovesicular fatty changes were observed in
56 patients (55%), microvesicular in 10 (10%), and mixed
form in 36 (35%). Fibrosis was present in 163 patients
(89%) with METAVIR F1 score in 66 (36%), F2 in 53 (29%),
F3 in 39 (21%) and F4 in 4 (2%). Necroinflammatory activ-
ity was detected in 164 out of the 184 (89%) patients with
A1 in 109 (59%), A2 in 50 (27%) and A3 in 5 (3%).
Factors associated with hepatic steatosis
Comparison of parameters in patients with or without HS
are presented in Table 2. In univariate analysis, intravenous
drug use (p=0.05) and HCV genotype 3 (p=0.005) were
strongly linked with HS. The median HCV viral load was
significantly higher in patients with HS compared with
those without (p=0.003). HS was also associated with
increased levels of ALT, ASTand decreased levels of serum
total cholesterol, but not with triglyceridemia nor available
parameters of metabolic syndrome (only 7 patients have a
glycemia >7 mmol/l with mild steatosis for 6 patients and
1 had no steatosis) (Table 2).
Also, there was no association with CD4 cell count or
an undetectable HIV viral load. Similar results were
found in patients with mild versus severe steatosis.
HS was also associated with fibrosis (Figure 1). Thus,
the frequency of HS increased with the stages of fibrosis,
with 76%, 54%, 32%, and 28% of patients without steato-
sis having fibrosis scores of F0, F1, F2, and F3–F4, re-
spectively (Cochran-Armitage trend test, p< 0.0001).
However, the severity of steatosis was not different
among patients presenting fibrosis scoring F1, F2, or
F3–F4. No association was observed between HS and
necroinflammatory activity.
Table 2 Comparison of various parameters in patients with mild (<33% of hepatocytes affected) or severe (>33% of
hepatocytes affected) steatosis and those without steatosis (univariate analysis)
No steatosis
(n = 82)
Steatosis
(n = 102)
Mild steatosis
(n = 76)
Severe steatosis
(n = 26)
p
a
p
b
p
c
Median age (IQR), yrs 40 (36-45) 41 (37-45) 41 (36-45) 41 (37-48) 0.38 0.66 0.81
Male gender, n (%) 66 (80) 88 (86) 67 (88) 21 (81) 0.32 0.39 0.34
IVDU, n (%) 50 (62) 77 (76) 54 (71) 23 (88) 0.05 0.03 0.11
Alcohol use, n (%) 29 (35) 38 (37) 29 (38) 9 (35) 0.88 0.92 0.82
Median duration of HIV (IQR), yrs 10 (5-14) 12 (8-14) 12 (8-15) 11 (7-13) 0.17 0.23 0.30
Median CD4 cell count (IQR),
/mm3
346 (228-560) 308 (227-423) 305 (227-435) 313 (191-398) 0.10 0.24 0.67
HIV RNA< 400 copies/ml, n (%) 58 (72) 61 (63) 46 (62) 15 (65) 0.26 0.45 1.0
HCV genotype 3, n (%) 13 (16) 34 (35) 18 (25) 16 (64) 0.005 <.0001 <.0001
Median HCV RNA (IQR), logIU/ml 5.97 (5.65-6.50) 6.30 (6.00-6.72) 6.22 (5.80-6.64) 6.69 (6.27-7.06) 0.003 0.0003 0.004
Median ALT (IQR), U/l 67 (40-119) 87 (54-130) 83 (51-121) 113 (84-132) 0.04 0.01 0.03
Median AST (IQR), U/l 56 (37-78) 77.5 (50-104) 70 (48-102) 78 (59-105) 0.001 0.003 0.33
Median alkaline phosphase (IQR),
U/l
90 (70-115) 89 (69-112) 90 (72-113) 80 (65-95) 0.46 0.27 0.15
Median GGT (IQR), U/l 71 (41-139) 87 (43-196) 92 (44-198) 73 (30-180) 0.09 0.09 0.19
Median glycemia (IQR), mmol/l 4.80 (4.30-5.45) 4.92 (4.30-5.22) 4.80 (4.30-5.20) 4.90 (4.35-5.26) 0.79 0.96 0.97
Glycemia ≥5.6 mmol/l, n (%) 16 (21) 17 (17) 12 (16) 5 (21) 0.56 0.77 0.76
Glycemia ≥7.0 mmol/l, n (%) 1 (1) 6 (6) 6 (8) 0 (0) 0.14 0.08 0.33
Median total cholesterol (IQR),
mmol/l
4.40 (3.73-5.33) 4.00 (3.30-4.79) 4.01 (3.30-5.03) 3.72 (3.06-4.37) 0.01 0.02 0.30
Median triglycerides (IQR),
mmol/l
1.47 (0.97-2.08) 1.51 (0.99-2.20) 1.53 (1.04-2.24) 1.23 (0.90-1.74) 0.86 0.51 0.28
Triglycerides ≥1.7 mmol/l, n (%) 30 (40) 30 (33) 23 (33) 7 (29) 0.33 0.56 0.80
Fibrosis F3-F4, n (%) 12 (15) 31 (30) 25 (33) 6 (23) 0.01 <0.001 1.0
Metavir score activity A2/A3,
n (%)
21 (26) 34 (33 ) 29 (38 ) 5 (19 ) 0.28 0.11 0.09
pa Comparison of patients with versus without steatosis (Kruskal-Wallis test for quantitative variables, χ2 test or Fisher's exact test for qualitative variables).
pb Comparison of patients with mild or severe steatosis versus without steatosis (Kruskal-Wallis test for quantitative variables, χ2 test for qualitative variables).
pc Comparison of patients with mild versus severe steatosis (Kruskal-Wallis/Wilcoxon test for quantitative variables, χ2 test or Fisher's exact test for qualitative
variables).
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After adjustment for the period of biopsy, neither the
type of ART nor the duration of exposure to a specific
antiretroviral agent or class of antiretroviral was related
to HS (Table 3). The same results were observed in
separate analyses among patients presenting genotype 3,
or another genotype (Tables 4 and 5).
In the multivariate analysis, only two independent fac-
tors remained associated with an increased risk of HS:
HCV genotype 3 (odds ratio [OR], 2.6; 95% confidence
intervals [CI], 1.1-6.3), and HCV RNA load (OR, 2.2 per
1 log higher; 95% CI, 1.2-3.8). Using a multivariate poly-
tomous logistic regression model, HCV genotype 3 and
HCV RNA load were moderately associated with mild
steatosis and strongly associated with severe steatosis
(Table 6).
Discussion
Hepatic steatosis has emerged as a major comorbidity in
HIV-HCV coinfected patients [13,35]. In this retrospect-
ive observational study of 184 HIV-HCV coinfected
patients ART-treated but untreated for HCV at the time
of liver biopsy, HS was present in about half patients
(55%), which is similar to rates of 24-75% found in other
studies of HIV-HCV coinfected and HCV monoinfected
patients [12,14-23,36]. In multivariate analysis, HS and
its severity were only significantly associated with HCV
genotype 3 and HCV viral load. Neither the type of ART,
nor their prolonged duration of exposure with a median
of near five years were related to steatosis. Moreover,
0
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%
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Fibrosis
None
Mild
Severe
Steatosis
Figure 1 Distribution of steatosis according to fibrosis index in
184 HIV-HCV coinfected patients treated with antiretroviral
therapy. Steatosis is defined as mild (<33% of hepatocytes affected)
or severe (>33% of hepatocytes affected).
Table 3 The effects on steatosis of exposure to specific antiretroviral medication in 184 HIV-HCV coinfected patients
Antiretrovirals n Exposure to ARV
Adjusted OR° (95% CI)
p Cumulative exposure duration
(per 1 year increase)
Adjusted OR (95% CI)
p
Nucleoside reverse
transcriptase inhibitors
184 NE 1.05 (0.96–1.16) 0.30
zidovudine 144 1.11 (0.54-2.30) 0.77 1.03 (0.91-1.16) 0.65
lamivudine 161 1.10 (0.44-2.77) 0.82 1.01 (0.88-1.17) 0.84
stavudine 114 0.96 (0.51-1.78) 0.88 1.05 (0.90-1.24) 0.54
didanosine 105 1.20 (0.66-2.18) 0.57 1.04 (0.85-1.27) 0.70
zalcitabine 22 1.68 (0.60-4.72) 0.33 1.50 (0.68-3.34) 0.31
tenofovir 24 0.87 (0.33-2.27) 0.78 1.19 (0.69-2.07) 0.53
abacavir 24 0.55 (0.22-1.39) 0.20 0.98 (0.69-1.41) 0.94
Protease inhibitors 126 1.15 (0.59-2.24) 0.67 1.06 (0.90-1.25) 0.50
ritonavir 55 0.90 (0.46-1.75) 0.75 0.96 (0.71-1.28) 0.76
indinavir 68 0.94 (0.51-1.74) 0.84 1.14 (0.87-1.47) 0.34
nelfinavir 47 0.96 (0.48-1.89) 0.91 1.12 (0.79-1.59) 0.54
saquinavir 31 0.91 (0.41-2.00) 0.81 0.72 (0.45-1.14) 0.16
lopinavir-ritonavir 17 0.55 (0.19-1.63) 0.28 0.86 (0.54-1.37) 0.52
atazanavir 8 0.76 (0.17-3.43) 0.72 0.99 (0.35-2.81) 0.98
Non-nucleoside reverse
transcriptase inhibitors
79 0.93 (0.50-1.74) 0.81 1.17 (0.88-1.55) 0.27
efavirenz 51 1.34 (0.67-2.69) 0.40 1.19 (0.88-1.63) 0.26
nevirapine 44 0.67 (0.33-1.35) 0.26 1.24 (0.77-2.00) 0.36
° Adjusted for period of liver biopsy.
Abbreviations: OR, odds ratio; CI, confidence intervals; NE, not estimable.
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ART have no differential effect on occurrence of HS
according to the genotype 3 compared to others.
We confirmed previously data of higher HS associated
with genotype 3 [23]. Here, the rate of severe HS (14%)
was higher in our study compared with 2-9% found in US
studies in HIV-HCV coinfected individuals [12], but was
similar with rates found in other studies [37,38], in particu-
lar with those conducted in France [39,40]. Several reasons
may explain these discrepancies. Whereas most of our
patients, and those included in the study of Bauerle et al.
[37], were Caucasian and carrying HCV genotype 3, other
studies have included a high proportion of Africo-Ameri-
can patients (47-94%) and patients infected with HCV
genotype 1 [38-45]. It is well-known that HCV-infected
Black people have a lower prevalence of HS than Cauca-
sian [41,45-47], probably related to lower visceral adipose
tissue [16,22].
HS is a frequent histological finding in patients with
chronic hepatitis C virus infection, particularly among
those infected with genotype 3 strain [24,48,49]. The preva-
lence of 26% of genotype 3 in our study was similar to the
prevalence of 18% reported in the French HepaVIH cohort
[50]. It has been postulated that genotype 1 is associated
with “metabolic” steatosis rather than “viral” steatosis
developed through a direct cytopathologic effect observed
especially in genotype 3 infected patients [51-56]. When we
examined the factors impacting the level of steatosis on
ART patients, genotype 3, and high HCV viral load were
two independent factors associated with HS in accordance
with previous studies [15,17,19,20]. Both factors moderately
increased the risk of mild steatosis, but were strongly asso-
ciated with severe steatosis (grade 2 or 3).
Other factors such as greater age [18], higher body mass
index (BMI) [12,15-18,20,22,38-40,42,44] [23], hypergly-
cemia [12], lower cholesterolemia [17], and presence of
lipodystrophy [17] have also been found to be independ-
ently associated with steatosis in coinfected patients. In
our study, patients with metabolic syndrome were not
more likely to present HS. However, only seven patients
had diabetes, and this limited sample size could have pre-
vent to study this risk factor. Moreover, as expected, ex-
posure to PIs and stavudine, were associated with elevated
triglycerides (p=0.08 and p< 0.0001, respectively), but this
metabolic abnormality was not a risk factors of HS in our
ART-experienced population. According to the lack of
data about HOMA scoring, weight and BMI, we probably
missed the impact of metabolic steatosis in genotype other
than 3 [23,41]. Other limitation of our retrospective study
is lack of information about alcohol consumption. Never-
theless, as described by Machado et al., metabolic syn-
drome and alcohol were not associated to HS. BMI was
considered an increasing risk factor but with small magni-
tude and diabetes as a possible risk factor with no data for
HOMA scoring [16,22]. Moreover, the higher percentage
Table 4 The effects on steatosis of exposure to specific antiretroviral medication in 184 HIV-HCV coinfected patients
according to the genotype
All patients (n = 184) Genotype 3 (n = 47) Other genotype (n = 132)
Antiretrovirals n Adjusted OR° (95% CI) p Adjusted OR° (95% CI) p Adjusted OR° (95% CI) p
NRTI 184 NE NE NE
zidovudine 144 1.11 (0.54–2.30) 0.77 0.91 (0.22-3.82) 0.90 1.42 (0.58-3.49) 0.45
lamivudine 161 1.10 (0.44–2.77) 0.82 0.50 (0.05-5.00) 0.56 1.29 (0.45-3.74) 0.64
stavudine 114 0.96 (0.51–1.78) 0.88 0.58 (0.14-0.47) 0.46 1.05 (0.51-2.17) 0.89
didanosine 105 1.20 (0.66–2.18) 0.57 1.02 (0.27-3.93) 0.97 1.17 (0.58-2.37) 0.66
zalcitabine 22 1.68 (0.60–4.72) 0.33 NE 1.29 (0.41-4.06) 0.66
tenofovir 24 0.87 (0.33–2.27) 0.78 0.15 (0.01-1.80) 0.13 1.44 (0.49-4.22) 0.51
abacavir 24 0.55 (0.22–1.39) 0.20 0.40 (0.07-2.40) 0.32 0.58 (0.18-1.84) 0.35
PI 126 1.15 (0.59–2.24) 0.67 0.19 -0.02-1.76) 0.15 1.46 (0.67-3.15) 0.34
ritonavir 55 0.90 (0.46–1.75) 0.75 0.54 (0.13-2.28) 0.40 1.04 (0.48-2.27) 0.91
indinavir 68 0.94 (0.51–1.74) 0.84 1.13 (0.29-4.41) 0.86 0.81 (0.39-1.68) 0.57
nelfinavir 47 0.96 (0.48–1.89) 0.91 0.37 (0.09-1.56) 0.18 1.19 (0.54-2.66) 0.66
saquinavir 31 0.91 (0.41–2.00) 0.81 0.41 (0.10-1.72) 0.22 0.94 (0.34-2.61) 0.91
lopinavir-ritonavir 17 0.55 (0.19–1.63) 0.28 0.45 (0.02-8.11) 0.59 0.67 (0.20-2.19) 0.50
atazanavir 8 0.76 (0.17–3.43) 0.72 NE 1.70 (0.31-9.24) 0.54
NNRTI 79 0.93 (0.50–1.74) 0.81 0.33 (0.08-1.27) 0.11 1.38 (0.65-2.95) 0.40
efavirenz 51 1.34 (0.67–2.69) 0.40 0.74 (0.17-3.27) 0.69 1.77 (0.79-4.00) 0.16
nevirapine 44 0.67 (0.33–1.35) 0.26 0.34 (0.08-1.38) 0.13 0.80 (0.35-1.83) 0.60
° Adjusted for period of liver biopsy.
Abbreviations: OR, odds ratio; CI, confidence intervals; NE, not estimable.
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of genotype 3 reflect the association between HS and HCV
viral parameters.
Many antiretroviral drugs have been associated with hep-
atic damage [57-59]. It has been suggested that steatosis
due to an accumulation of fatty acids in the hepatocytes
could be a consequence of mitochondrial dysfunction, sec-
ondary to drugs or viruses inducing oxidative stress [60].
The effect of the drug class and drugs within classes on HS
in HIV-HCV coinfected patients remain unclear. Previously,
some studies reported no significant association between
HS and ART as in our study [12,15,16,18,41]. When focus-
ing on the use of stavudine, a medication closely linked with
HS and lipodystrophy syndrome resulting from mitochon-
drial damage, Sulkowski et al. [45] found that stavudine ex-
posure was a risk factor for steatosis like in the study of
Borghi et al., whereas no such association was found for this
drug as well as the D-drug group of antiretrovirals (didano-
sine, zalcitabine) in other studies [23,38,41,42,61,62]. Re-
cently, in a meta-analysis of the risk factors associated with
HS in HIV-HCV patients, Machado et al. failed to find any
association with antiretrovirals of any class and HS as well
as in our study [16,22]. Moreover, Woreta et al., showed in
a study including a majority of Black patients (87%) with
94% genotype 1, the lack of association with antiretroviral
drugs with a median cumulative drug exposure similar to
ours [41]. Despite its relatively small sample size, our study
had a statistical power of 80% to detect an increased risk of
steatosis of 3 for the antiretroviral drugs used less fre-
quently such as abacavir, tenofovir and lopinavir. We could
hypothesize that discrepancies with other studies were
linked to the differential prevalence of Caucasion subjects,
of metabolic characteristics and frequency of genotype 1
Table 6 Results from multivariate polytomous logistic regression analyses of factors associated with mild (<33% of
hepatocytes affected ) and severe (>33% of hepatocytes affected) steatosis in 184 HIV-HCV coinfected patients treated
with antiretroviral therapy
Mild steatosis AOR (95%CI) p Severe steatosis AOR (95%CI) p
HCV genotype 3 1.76 (0.72-4.30) 0.22 19.51 (4.49-84.73) <0.0001
HCV RNA (per 1 log10 increase) 1.80 (1.02-3.16) 0.04 14.86 (3.79-58.22) 0.0001
Abbreviations: AOR, adjusted odds ratio; CI, confidence intervals.
Table 5 The effects on steatosis of cumulative exposure duration to specific antiretroviral medication in 184 HIV-HCV
coinfected patients according to the genotype
All patients (n = 184) Genotype 3 (n = 47) Other genotype (n = 132)
Antiretrovirals Cumulative exposure duration
(per 1 year increase)
Adjusted OR (95% CI)
p Cumulative exposure duration
(per 1 year increase)
Adjusted OR (95% CI)
p Cumulative exposure duration
(per 1 year increase)
Adjusted OR (95% CI)
p
Nucleoside reverse
transcriptase inhibitors
1.05 (0.96-1.16) 0.30 1.07 (0.85-1.35) 0.55 1.03 (0.92-1.15) 0.64
zidovudine 1.03 (0.91-1.16) 0.65 1.01 (0.81-1.27) 0.92 1.00 (0.86-1.17) 0.98
lamivudine 1.01 (0.88-1.17) 0.84 0.99 (0.75-1.32) 0.97 0.99 (0.84-1.17) 0.92
stavudine 1.05 (0.90-1.24) 0.54 1.16 (0.81-1.68) 0.41 0.99 (0.81-1.22) 0.94
didanosine 1.04 (0.85-1.27) 0.70 1.08 (0.64-1.81) 0.77 1.04 (0.83-1.29) 0.75
zalcitabine 1.50 (0.68-3.34) 0.31 NE 1.35 (0.57-3.16) 0.49
tenofovir 1.19 (0.69-2.07) 0.53 0.29 (0.03-2.49) 0.26 1.46 (0.80-2.66) 0.22
abacavir 0.98 (0.69-1.41) 0.94 1.14 (0.54-2.41) 0.73 0.88 (0.56-1.41) 0.61
Protease inhibitors 1.06 (0.90-1.25) 0.50 1.14 (0.82-1.59) 0.44 0.98 (0.80-1.21) 0.87
ritonavir 0.96 (0.71-1.28) 0.76 0.88 (0.45-1.74) 0.72 1.00 (0.71-1.40) 0.98
indinavir 1.14 (0.87-1.47) 0.34 NE 0.89 (0.63-1.25) 0.50
nelfinavir 1.12 (0.79-1.59) 0.54 1.06 (0.63-1.76) 0.83 1.11 (0.66-1.87) 0.68
saquinavir 0.72 (0.45-1.14) 0.16 0.67 (0.33-1.36) 0.26 0.54 (0.25-1.19) 0.13
lopinavir-ritonavir 0.86 (0.54-1.37) 0.52 0.90 (0.13-6.28) 0.92 0.89 (0.54-1.46) 0.64
atazanavir 0.99 (0.35-2.81) 0.98 NE 1.53 (0.43-5.47) 0.51
Non-nucleoside reverse
transcriptase inhibitors
1.17 (0.88-1.55) 0.27 1.04 (0.60-1.82) 0.89 1.25 (0.90-1.75) 0.18
efavirenz 1.19 (0.88-1.63) 0.26 1.08 (0.56-2.09) 0.82 1.28 (0.89-1.83) 0.18
nevirapine 1.24 (0.77-2.00) 0.36 0.47 (0.19-1.20) 0.57 1.18 (0.67-2.08) 0.56
° Adjusted for period of liver biopsy.
Abbreviations: OR, odds ratio; CI, confidence intervals; NE, not estimable.
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and 3. Borghi et al. evocated a putative role of ART in the
occurrence of HS in patients infected with genotypes other
than 3 [23] but in our study, the impact of ART on HS was
not different between genotype 3 and the others.
In conclusion, for our Caucasian cohort predomin-
antly infected with genotype-HCV 1, hepatic steatosis in
HIV-HCV coinfected patients receiving antiretroviral
therapy is associated with HCV-related factors particu-
larly in genotype 3 patients but not antiretrovirals.
Nevertheless, as showed in our study, ART seems play a
minor role in HS since the choose and use of more
"metabolically friendly" antiretroviral drugs. Overall, we
found only viral parameters, HCV genotype 3, and HCV
RNA value, which were strongly associated with HS,
particularly a severe steatosis. Among HIV-HCV co-
infected patients receiving ART and who had never been
treated for HCV, neither the type of drugs nor the dur-
ation of exposure was related to HS whatever the
genotype.
Abbreviations
HIV: human immunodeficiency virus; HCV: hepatitis C virus; ART: antiretroviral
therapy; ALT: alanine aminotransferase; AST: aspartate aminotransferase;
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